The anti-infective agents market in Italy is expected to reach a projected revenue of US$ 5,351.9 million by 2033. A compound annual growth rate of 1.6% is expected of Italy anti-infective agents market from 2026 to 2033.
The Italy anti-infective agents market generated a revenue of USD 4,860.3 million in 2025 and is expected to reach USD 5,351.9 million by 2033.
The Italy market is expected to grow at a CAGR of 1.6% from 2026 to 2033.
In terms of segment, antivirals was the largest revenue generating type in 2025.
Antifungals is the most lucrative type segment registering the fastest growth during the forecast period.
Anti-infective agents market data book summary
Market revenue in 2025
USD 4,860.3 million
Market revenue in 2033
USD 5,351.9 million
Growth rate
1.6% (CAGR from 2026 to 2033)
Largest segment
Antivirals
Fastest growing segment
Antifungals
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Antibacterials, Antivirals, Antifungals
Key market players worldwide
Pfizer Inc, Abbott Laboratories, Gilead Sciences Inc, Bristol-Myers Squibb Co, Merck & Co Inc, Sandoz Group AG ADR, B. Braun, Novo Holdings, Mankind Pharma, Bayer AG, AstraZeneca PLC, Boehringer Ingelheim Pharma
Other key industry trends
In terms of revenue, Italy accounted for 3.6% of the global anti-infective agents market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, UK anti-infective agents market is projected to lead the regional market in terms of revenue in 2033.
UK is the fastest growing regional market in Europe and is projected to reach USD 9,148.0 million by 2033.
The anti-infective agents market in Italy is experiencing growth, supported by government funding and collaborative efforts to combat antimicrobial resistance (AMR). Recognizing the public health threat posed by drug-resistant infections, the Italian government is actively investing in initiatives to drive the development of new treatments.
In October 2024, the Italian government awarded USD 21 million to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to support its mission to advance new antibiotics, vaccines, and rapid diagnostics targeting infections that resist existing treatments. CARB-X plays a crucial role in accelerating innovation in anti-infectives.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Anti-infective Agents Market Outlook will help companies and investors design strategic landscapes.
Antivirals was the largest segment with a revenue share of 57.78% in 2025.
Horizon Databook has segmented the Italy anti-infective agents market based on antibacterials, antivirals, antifungals covering the revenue growth of each sub-segment from 2021 to 2033.
The anti-infective agents market in Italy is experiencing growth, supported by government funding and collaborative efforts to combat antimicrobial resistance (AMR). Recognizing the public health threat posed by drug-resistant infections, the Italian government is actively investing in initiatives to drive the development of new treatments.
In October 2024, the Italian government awarded USD 21 million to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to support its mission to advance new antibiotics, vaccines, and rapid diagnostics targeting infections that resist existing treatments. CARB-X plays a crucial role in accelerating innovation in anti-infectives.
Italy Anti-Infective Agents Market Type Outlook (Revenue, USD Million , 2021-2033)
Antibacterials
Antivirals
Antifungals
Italy Anti-Infective Agents Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
Oral
Parenteral
Topical
Others
Italy Anti-Infective Agents Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Others
Reasons to subscribe to anti infective agents market databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of anti infective agents market databook
Our clientele includes a mix of anti infective agents market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy anti infective agents market, including forecasts for subscribers. This country databook contains high-level insights into Italy anti infective agents market from 2021 to 2033, including revenue numbers, major trends, and company profiles.